Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light-Activated nanoparticles could target sarcomas

NCT ID NCT06599957

Knowledge-focused Sponsor: Istituto Ortopedico Rizzoli Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is developing a new way to deliver chemotherapy directly to sarcoma tumors using tiny particles activated by light through an optic fiber. Researchers will test these nanoparticles on cells and tissue samples from 30 patients with bone or soft tissue sarcomas. The goal is to see if this approach can kill tumor cells more effectively than standard chemotherapy, with the hope of one day treating inoperable tumors or cancer that has spread.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nanocarriers loaded with chemotherapeutic agents delivered via optoporation (optic fiber)
What this could lead to
If successful, this could lead to a new way to deliver chemotherapy directly to inoperable sarcomas, potentially reducing side effects and improving treatment.
What could go wrong
This is a very early, lab-based study on patient cells, not yet tested in humans. The technology may not work as hoped or may have unforeseen safety issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients affected by sarcoma and undergoing surgical removal of the tumor or performing a biopsy will be enrolled. Only patients whose resection will provide sufficient tumor tissue that exceed what is necessary for pathological diagnosis characterization and banking will be enrolled.

Ages

2 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients eligible for the study will be male or female, with an age ranging from 0- to 85 years, undergoing surgery or biopsy for STSs or BSs including osteosarcomas. * Included patients may have undergone or may be still in treatment with chemotherapy (also neo-adjuvant settings), targeted therapy, radiotherapy, or combination therapy. * IRST will enroll only adult patients (age \> 18 years). * Signed informed consent from all subjects enrolled in the study. IOR patients will have to sign both the specific project Informed Consent and the IOR Biobank Informed consent. Exclusion Criteria: * Patients not affected by STSs or BSs will be excluded from the study, as well as patients with multiple primary tumors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone and soft tissue tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone sarcoma connective and soft tissue neoplasm osteosarcoma sarcoma Soft Tissue Neoplasms soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone and soft tissue tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori

    RECRUITING

    Meldola, Emilia-Romagna, 47014, Italy

  • Istituto Ortopedico Rizzoli-OSOTT

    RECRUITING

    Bologna, Emilia-Romagna, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.